nafarelin and Osteoporosis--Postmenopausal

nafarelin has been researched along with Osteoporosis--Postmenopausal* in 2 studies

Reviews

1 review(s) available for nafarelin and Osteoporosis--Postmenopausal

ArticleYear
Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review.
    Sao Paulo medical journal = Revista paulista de medicina, 2008, Volume: 126, Issue:5

    Osteoporosis is defined as a disease characterized by low bone mass and deterioration of the bone tissue microarchitecture. Teriparatide stimulates the formation and action of osteoblasts, which are responsible for bone formation, thus promoting bone tissue increase. The aim was to assess the effectiveness and safety of teriparatide for treating postmenopausal osteoporosis.. A systematic review was conducted using the Cochrane Collaboration methodology.. 1) Teriparatide 20 microg or 40 microg versus placebo: there was a benefit from teriparatide, considering the following outcomes: reduction in the number of new vertebral and non-vertebral fractures, and increased whole-body, lumbar and femoral bone mineral density. 2) Teriparatide 40 microg versus alendronate 10 mg/day for 14 months: there was no statistical difference regarding the incidence of new vertebral or non-vertebral fractures, although in the group that received teriparatide there was greater bone mineral density increase in the whole body, lumbar column and femur. 3) Estrogen plus teriparatide 25 microg versus estrogen: there was a benefit, considering the following outcomes: reduction in the number of new vertebral fractures, and increased whole-body, lumbar and femoral bone mineral density after three years.. When teriparatide is intermittently administered in low doses, it reduces the incidence of vertebral fractures (67%) and non-vertebral fractures (38%) and increases bone mineral density in the lumbar column and femur. There is a need for studies with longer observation in order to allow conclusions regarding the safety and duration of the therapeutic effects.

    Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Estrogens; Female; Fertility Agents, Female; Humans; Middle Aged; Nafarelin; Osteoporosis, Postmenopausal; Teriparatide

2008

Trials

1 trial(s) available for nafarelin and Osteoporosis--Postmenopausal

ArticleYear
Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 1990, Volume: 4, Issue:4

    Medical 'oophorectomy' by GnRH agonist or danazol is an effective treatment for endometriosis. Since increased bone loss is a potential risk of hypoestrogenism, we compared the effect of nafarelin and danazol treatment on bone metabolism. Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400 micrograms day intranasally) and six patients danazol (600 mg day orally) for 6 months. Both treatments had already led to hypoestrogenism (E2 less than 21.6 pg/ml) after 3 months. They both were accompanied by an approximately 50% rise in 24-h urinary hydroxyproline output, suggesting accelerated bone resorption at 6 months; yet urinary calcium output did not change significantly. Serum osteocalcin rose by 80-120% and bone alkaline phosphatase activity by 34-40%, suggesting stimulated bone formation at the same time. No detectable changes ensued in cortical bone mineral content in the distal radius or in serum levels of calcium, calcitonin, parathyroid hormone, or aminoterminal propeptide of type III collagen. Three months after treatment, hydroxyproline output, serum osteocalcin and bone alkaline phosphatase were still elevated in women taking nafarelin, whereas only serum osteocalcin was elevated in women taking danazol. Our data thus suggest that bone turnover was increased during nafarelin and danazol therapy and that this effect was reversible.

    Topics: Alkaline Phosphatase; Analysis of Variance; Bone Density; Bone Regeneration; Calcitonin; Calcium; Danazol; Endometriosis; Female; Gonadotropin-Releasing Hormone; Humans; Hydroxyproline; Middle Aged; Nafarelin; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptide Fragments; Procollagen

1990
chemdatabank.com